CN104837855B - 选择的具有pde4抑制活性的大环内酯 - Google Patents

选择的具有pde4抑制活性的大环内酯 Download PDF

Info

Publication number
CN104837855B
CN104837855B CN201380064602.7A CN201380064602A CN104837855B CN 104837855 B CN104837855 B CN 104837855B CN 201380064602 A CN201380064602 A CN 201380064602A CN 104837855 B CN104837855 B CN 104837855B
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
macrocyclic lactone
acceptable salt
compound
lactone compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380064602.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN104837855A (zh
Inventor
J·L·克伦贝热
J·德雷耶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Beihede Pharmaceutical Technology Co ltd
Original Assignee
BASLIER PHARMACEUTICAL AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASLIER PHARMACEUTICAL AG filed Critical BASLIER PHARMACEUTICAL AG
Publication of CN104837855A publication Critical patent/CN104837855A/zh
Application granted granted Critical
Publication of CN104837855B publication Critical patent/CN104837855B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201380064602.7A 2012-12-31 2013-12-27 选择的具有pde4抑制活性的大环内酯 Active CN104837855B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12199801.7 2012-12-31
EP12199801 2012-12-31
EP13158812 2013-03-12
EP13158812.1 2013-03-12
PCT/EP2013/078040 WO2014102315A1 (en) 2012-12-31 2013-12-27 Selected macrolides with pde4-inhibiting activity

Publications (2)

Publication Number Publication Date
CN104837855A CN104837855A (zh) 2015-08-12
CN104837855B true CN104837855B (zh) 2017-03-01

Family

ID=49886948

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380064602.7A Active CN104837855B (zh) 2012-12-31 2013-12-27 选择的具有pde4抑制活性的大环内酯

Country Status (11)

Country Link
US (2) US9738676B2 (enExample)
EP (1) EP2938623B1 (enExample)
JP (1) JP6154026B2 (enExample)
CN (1) CN104837855B (enExample)
CA (1) CA2889251A1 (enExample)
DK (1) DK2938623T3 (enExample)
ES (1) ES2607638T3 (enExample)
HU (1) HUE030196T2 (enExample)
PL (1) PL2938623T3 (enExample)
PT (1) PT2938623T (enExample)
WO (1) WO2014102315A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200112898A (ko) 2018-01-19 2020-10-05 쉔양 푸양 파마슈티컬 테크놀로지 컴퍼니 리미티드 캐리마이신 또는 이의 활성 성분의 용도
CN110051680B (zh) * 2018-01-19 2022-02-18 沈阳福洋医药科技有限公司 一种用于预防和/或治疗阿尔茨海默病的药物、组合产品及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1464880A (zh) * 2000-08-22 2003-12-31 巴斯利尔药物股份公司 具有抗细菌活性的新的大环内酯
CN1630661A (zh) * 2002-02-28 2005-06-22 巴斯利尔药物股份公司 具有抗菌活性的大环内酯类化合物
CN101939327A (zh) * 2008-02-08 2011-01-05 巴斯利尔药物股份公司 新的大环内酯类及其用途
WO2011018510A1 (en) * 2009-08-13 2011-02-17 Basilea Pharmaceutica Ag New macrolides and their use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE427315T1 (de) * 2005-02-09 2009-04-15 Basilea Pharmaceutica Ag Neue makrolide
CN103142632B (zh) * 2008-02-08 2016-01-20 巴斯利尔药物股份公司 通过抑制pde而介导的用于治疗疾病的大环内酯类

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1464880A (zh) * 2000-08-22 2003-12-31 巴斯利尔药物股份公司 具有抗细菌活性的新的大环内酯
CN1630661A (zh) * 2002-02-28 2005-06-22 巴斯利尔药物股份公司 具有抗菌活性的大环内酯类化合物
CN101939327A (zh) * 2008-02-08 2011-01-05 巴斯利尔药物股份公司 新的大环内酯类及其用途
WO2011018510A1 (en) * 2009-08-13 2011-02-17 Basilea Pharmaceutica Ag New macrolides and their use

Also Published As

Publication number Publication date
JP2016504343A (ja) 2016-02-12
WO2014102315A1 (en) 2014-07-03
HUE030196T2 (en) 2017-04-28
DK2938623T3 (en) 2017-01-09
JP6154026B2 (ja) 2017-06-28
US20170327525A1 (en) 2017-11-16
HK1210618A1 (en) 2016-04-29
US20150344515A1 (en) 2015-12-03
CN104837855A (zh) 2015-08-12
PL2938623T3 (pl) 2017-03-31
CA2889251A1 (en) 2014-07-03
EP2938623A1 (en) 2015-11-04
US9738676B2 (en) 2017-08-22
ES2607638T3 (es) 2017-04-03
EP2938623B1 (en) 2016-10-05
PT2938623T (pt) 2016-11-23
US10221206B2 (en) 2019-03-05

Similar Documents

Publication Publication Date Title
AU2011336272A1 (en) 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
BRPI0313664B1 (pt) Compostos inibidores de nucleosídeo fosforilase e nucleosidases, suas composições e seus usos
EP2464651B1 (en) New macrolides and their use
IL167882A (en) 9a-AZALIDES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM
CN104837855B (zh) 选择的具有pde4抑制活性的大环内酯
EP2245038B1 (en) New macrolides and their use
JP6767011B2 (ja) 抗ｄｎａウィルス活性などの生理活性を有するヌクレオシド誘導体
EP3406612A1 (en) Carboline derivative serving as bromodomain inhibitor
WO2018053302A1 (en) Macrocyclic compounds for the inhibition of indoleamine-2,3-dioxygenase activity and use thereof
EP3355888A1 (en) Hemi-synthetic trilobine analogs for use as a drug
AU2005210032B9 (en) Macrolides with antiinflammatory activity
HK1210618B (en) Selected macrolides with pde4-inhibiting activity
EP2897970B1 (en) Macrolide derivatives, preparation thereof and therapeutic use thereof
EP2440533B1 (en) Guanine riboswitch binding compounds and their use as antibiotics
EP3842430B1 (en) Set8 lysine methyltransferase inhibitor, preparation method therefor, and use thereof
EP0508726A1 (en) Novel process for the preparation of 9-deoxo-8a-aza-8a-homoerythromycin a and its 8a-alkyl derivatives
EP0508725A1 (en) Novel process for the preparation of 8a-aza-8a-homoerythromycin cyclic iminoethers
KR20140019279A (ko) 신규 항균 화합물들, 이의 제조 방법들, 및 그의 용도
WO2022211627A1 (en) Inhibitors of nicotinamide n-methyl transferase (nnmt)
WO2013178622A1 (en) New monosaccharide derivatives and biological applications thereof
CN102603759B (zh) 喜树碱e环类似物及其作为药物的用途
EP0508795A1 (en) 8a-aza-8a-homoerythromycin cyclic iminoethers
Qi et al. Design and synthesis of macrocyclic polyoxazoles
EP3483155B1 (en) Spiro three-membered ring or spiro five-membered ring peptide deformylase inhibitor and use thereof as an anti-tumour agent
CN120904264A (zh) 抗病毒核苷类似物、制备方法及其用途

Legal Events

Date Code Title Description
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1210618

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1210618

Country of ref document: HK

TR01 Transfer of patent right

Effective date of registration: 20181129

Address after: 638 Xiushan Road, Haimen City, Jiangsu Province

Patentee after: Basilea Pharmaceutica China Ltd.

Address before: Basel

Patentee before: Baslier Pharmaceutical AG

TR01 Transfer of patent right
CP01 Change in the name or title of a patent holder

Address after: 226100, Xiushan East Road, Haimen, Jiangsu, No. 638

Patentee after: Jiangsu beihede Pharmaceutical Technology Co.,Ltd.

Address before: 226100, Xiushan East Road, Haimen, Jiangsu, No. 638

Patentee before: Barcelona Pharmaceutical (China) Co.,Ltd.

CP01 Change in the name or title of a patent holder